Inventor · disambiguated record
Meizhong Jin
Also filed as: JIN MEIZHONG
24 granted patents·17 pending applications·188 citations·filing 2006–2024
95Inventor score
Files withENANTA PHARM INC13REVOLUTION MEDICINES INC6ARVINAS OPERATIONS INC5ARVINAS INC4OSI PHARM INC3
Top patents by PatentIndex Score
41 records- 0198US10189846B2Hepatitis B antiviral agentsENANTA PHARM INC·Filed 2017·Granted Jan 29, 2019·25 cites·8 claims
- 0298US10179131B2Hepatitis B antiviral agentsENANTA PHARM INC·Filed 2016·Granted Jan 15, 2019·27 cites·15 claims
- 0397US10730870B2Compounds and methods for the enhanced degradation of targeted proteinsARVINAS INC·Filed 2016·Granted Aug 4, 2020·25 cites·22 claims
- 0496US10538532B2Hepatitis B antiviral agentsENANTA PHARM INC·Filed 2018·Granted Jan 21, 2020·17 cites·15 claims
- 0595US10179792B2Hepatitis B antiviral agentsENANTA PHARM INC·Filed 2017·Granted Jan 15, 2019·17 cites·13 claims
- 0694US10640511B2Hepatitis B antiviral agentsENANTA PHARM INC·Filed 2018·Granted May 5, 2020·13 cites·11 claims
- 0793US10934306B2Hepatitis B antiviral agentsENANTA PHARM INC·Filed 2019·Granted Mar 2, 2021·5 cites·12 claims
- 0891US7923555B2Fused bicyclic mTor inhibitorsOSI PHARM INC·Filed 2008·Granted Apr 12, 2011·15 cites·2 claims
- 0989US8314111B2Fused bicyclic motor inhibitorsCHEN XIN·Filed 2011·Granted Nov 20, 2012·12 cites·2 claims
- 1088US11352351B2Compounds and methods for the targeted degradation of androgen receptorARVINAS INC·Filed 2016·Granted Jun 7, 2022·4 cites·16 claims
- 1188US7943767B2Fused bicyclic mTOR inhibitorsOSI PHARM INC·Filed 2009·Granted May 17, 2011·9 cites·14 claims
- 1287US8796455B2Fused bicyclic mTOR inhibitorsCHEN XIN·Filed 2013·Granted Aug 5, 2014·8 cites·10 claims
- 1384US11512083B2Compounds and methods for the enhanced degradation of targeted proteinsARVINAS OPERATIONS INC·Filed 2020·Granted Nov 29, 2022·1 cites·17 claims
- 1479US8481733B2Substituted imidazopyr- and imidazotri-azinesCREW ANDREW P·Filed 2009·Granted Jul 9, 2013·7 cites·16 claims
- 1578US12264157B2Compounds and methods for the enhanced degradation of targeted proteinsARVINAS OPERATIONS INC·Filed 2022·Granted Apr 1, 2025·0 cites·24 claims
- 1677US2025206715A1Compounds that participate in cooperative binding and uses thereofREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 1776US2024059686A1Compounds and methods for the targeted degradation of the androgen receptorARVINAS OPERATIONS INC·Filed 2022·Application pending·0 cites
- 1875US2024426833A1Methods and reagents for analyzing protein-protein interfacesREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 1974US12054493B2Hepatitis B antiviral agentsENANTA PHARM INC·Filed 2021·Granted Aug 6, 2024·0 cites·10 claims
- 2074US2024299366A1Imide-based modulators of proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2023·Application pending·0 cites
- 2171US9351974B2Substituted pteridinones for the treatment of cancerOSI PHARMACEUTICALS LLC·Filed 2012·Granted May 31, 2016·2 cites·10 claims
- 2271US2024139185A1Compounds that participate in cooperative binding and uses thereofREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 2365US10702528B2Hepatitis B antiviral agentsENANTA PHARM INC·Filed 2018·Granted Jul 7, 2020·0 cites·14 claims
- 2465US2022089570A1Imide-based modulators of proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2021·Application pending·0 cites
- 2565US2020317678A1Hepatitis b antiviral agentsENANTA PHARM INC·Filed 2020·Application pending·0 cites
- 2663US8445510B2Fused bicyclic kinase inhibitorsMULVIHILL MARK J·Filed 2011·Granted May 21, 2013·1 cites·15 claims
- 2762US2020197391A1Compounds that participate in cooperative binding and uses thereofREVOLUTION MEDICINES INC·Filed 2019·Application pending·0 cites
- 2857US2011190496A1FUSED BICYCLIC mTOR INHIBITORSOSI PHARM INC·Filed 2011·Application pending·0 cites
- 2955US2021285955A1Methods and reagents for analyzing protein-protein interfacesREVOLUTION MEDICINES INC·Filed 2018·Application pending·0 cites
- 3054US2020199102A1Compounds that participate in cooperative binding and uses thereofREVOLUTION MEDICINES INC·Filed 2018·Application pending·0 cites
- 3152US2016058872A1Imide-based modulators of proteolysis and associated methods of useARVINAS INC·Filed 2015·Application pending·0 cites
- 3250US8022206B2Furo[3,2-C]pyridinesOSI PHARMACEUTICALS LLC·Filed 2009·Granted Sep 20, 2011·0 cites·19 claims
- 3349US2013253197A1Fused bicyclic kinase inhibitorsOSI PHARMACEUTICALS LLC·Filed 2013·Application pending·0 cites
- 3446US2007129364A1Pyrrolopyridine kinase inhibiting compoundsDONG HAN-QING·Filed 2006·Application pending·0 cites
- 3545US10738035B2Hepatitis B antiviral agentsENANTA PHARM INC·Filed 2016·Granted Aug 11, 2020·0 cites·9 claims
- 3644US10442788B2Hepatitis B antiviral agentsENANTA PHARM INC·Filed 2016·Granted Oct 15, 2019·0 cites·15 claims
- 3742US2014088114A1Fused bicyclic kinase inhibitorsJIN MEIZHONG·Filed 2012·Application pending·0 cites
- 3841US10301255B2Hepatitis B antiviral agentsENANTA PHARM INC·Filed 2016·Granted May 28, 2019·0 cites·16 claims
- 3941US2015291562A1Imide-based modulators of proteolysis and associated methods of useARVINAS INC·Filed 2015·Application pending·0 cites
- 4040US10280175B2Hepatitis B antiviral agentsENANTA PHARM INC·Filed 2017·Granted May 7, 2019·0 cites·19 claims
- 4136US2012220595A1Deuterated Tyrosine Kinase InhibitorsEPSTEIN DAVID M·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Meizhong Jin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →